Abstract: Aim The pharmacokinetic paramneters and relative bioavailability of capsule A (Maiwei Pharmaceutical Co Ltd, Bejjing, China) and capsule B (Xianjing Pharmaceutical, Hunan, China) were studied. Methods A single oral dose of 600 mg gemfibrozil of these two kinds of capsules was given to 12 chinese healthy male volunteers in an open，randomized crossover study. Plasma levels were determined with HPLC-UV method.Results The plasma concentration-time curve was fitted to 1-compartment open model with a first order and lag time absorption and the major pharmacokinetic parameters of capsules A and B were shown respectively as following:C_max (32.69+5.67)and (29.41+2.60) mg·L^-1;T_max(1.01+0.14) and (1.13+0.37) h,t1/2ka(0.46士0.18) and (0.62+0.20) h;C_max(1.11土0.32) and (1.32+0.26) h;MRT(2.14土0.27) and (2.37+0.26) h;AUC (91.7+13.2) and (82.2土 7.38) mg·h·L^-1. There were no significantly differences between the pharmacokinetic parameters of capsule A and B. The relative bioavailability of the capsule A was (110土9)% as compared to the capsule B.Conclusion The two kinds of capsules have the equivalent biological effects.

Key words: gemfibrozil, pharmacokinetics, relative bioavailability, HPLC, human